Additional file 1 of GSH-responsive degradable nanodrug for glucose metabolism intervention and induction of ferroptosis to enhance magnetothermal anti-tumor therapy

Abstract

Additional file 1: Figure S1. Representative TEM images of LFMP. Figure S2. T2-weighted MR imaging (A) and transverse relaxivity (r2) of LFMP was examined by a clinical 3.0 T MR imaging device with a T2 mapping sequence (B). The quantitative assay was performed by measuring the intensity of MR images using ImageJ software (C). Data shown as mean ± SD, n = 5, **p < 0.01, ***p < 0.001. Figure S3. Biocompatibility of different concentrations of LFMP in blood for 4 h. H2O as positive control, 0.9% NaCl as negative control. Figure S4. Representative TEM images of biodegradation behavior of LFMP in PBS solution ([GSH] = 10 mM) for 10 days (scale bar = 50 μm). Figure S5. Half-maximal inhibitory concentration (IC50) of LND (A), FMP (B), FMP + AMF (B), LFMP (C), and LFMP + AMF(C) in EMT-6 cells. The data are presented as the mean ± SD, n = 6. Figure S6. Combination index plot for drug combination of LND and FMP. Figure S7. TUNEL staining and the corresponding proportion of TUNEL positive cells of tumor sections after the survival experiment (Scale bar = 100 μm). The data was shown as mean ± SD, n = 6 per group, ***p < 0.001. Figure S8. Blood biochemical indexes and hematology parameters of the mice with different treatments. The data are presented as the mean ± SD, n = 6. Table S1. Physicochemical properties of FM and LFMP. Table S2. Hydrodynamic diameter distributions and Zeta potential of LFMP in different solutions. Data are presented as mean ± SD, n = 6